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Abstract: Background and Aims: Clinical evidence for the benefits of branched-chain amino acids
(BCAAs) is lacking in advanced liver disease. We evaluated the potential benefits of long-term oral
BCAA supplementation in patients with advanced liver disease. Methods: Liver cirrhosis patients
with Child–Pugh (CP) scores from 8 to 10 were prospectively recruited from 13 medical centers.
Patients supplemented with 12.45 g of daily BCAA granules over 6 months, and patients consuming
a regular diet were assigned to the BCAA and control groups, respectively. The effects of BCAA
supplementation were evaluated using the model for end-stage liver disease (MELD) score, CP score,
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serum albumin, serum bilirubin, incidence of cirrhosis-related events, and event-free survival for
24 months. Results: A total of 124 patients was analyzed: 63 in the BCAA group and 61 in the
control group. The MELD score (p = 0.009) and CP score (p = 0.011) significantly improved in the
BCAA group compared to the control group over time. However, the levels of serum albumin and
bilirubin in the BCAA group did not improve during the study period. The cumulative event-free
survival was significantly improved in the BCAA group compared to the control group (HR = 0.389,
95% CI = 0.221–0.684, p < 0.001). Conclusion: Long-term supplementation with oral BCAAs can
potentially improve liver function and reduce major complications of cirrhosis in patients with
advanced liver disease.
Keywords: amino acids; branched-chain; liver cirrhosis; prognosis; ascites; hepatic encephalopathy
1. Introduction
Protein-calorie malnutrition is a progressing condition caused by underlying chronic liver disease
and poor nutritional support [1,2]. As chronic liver disease progresses to decompensated cirrhosis,
more than 60% of patients suffer from malnutrition, which worsens their quality of life and increases
their mortality rate [1,3]. Although most of the conditions underlying chronic liver disease, including
chronic hepatitis B (CHB) and chronic hepatitis C, have been relatively well controlled by recent
advances in antiviral treatments, malnutrition is frequently underevaluated in clinical practice [4].
The adverse impacts of malnutrition are related to the progression of liver disease in patients with
alcoholic liver disease [5]. Sarcopenia, which is characterized by a low skeletal muscle mass, is also
known to be related to the prognosis in patients with any etiology of chronic liver disease, including
nonalcoholic fatty liver disease [6,7].
As hepatic function worsens, decreasing hepatic ureagenesis impairs the disposal pathway for
blood ammonia. In addition, impairment of plasma protein synthesis induces hypoproteinemia
and decreases the skeletal muscle mass [8]. Initially, branched-chain amino acids (BCAAs) are not
catabolized in the liver but in peripheral tissues due to lack of BCAA aminotransferase (BCAT) in the
liver [9]. Though skeletal muscle has high BCAT activity, which is a major organ for BCAA catabolism,
the liver has the highest activity of branched-chain α-keto acid dehydrogenase for the cooperation of
BCAA catabolism [10]. The demand for BCAAs is increased in cirrhotic patients with portosystemic
shunt and malnutrition owing to the ammonia being converted into glutamine in skeletal muscle and
brain [4]. The depletion of BCAAs is aggravated by the hypermetabolic state of cirrhosis, poor oral
intake, and malabsorption [11].
The beneficial effects of BCAA supplementation in liver disease include improvements in
body composition and nitrogen balance, liver cell regeneration, protein and albumin synthesis,
hepatic encephalopathy, and immune function [12]. However, a recently updated Cochrane review
concluded that there were no beneficial effects on mortality, quality of life, or parameters related to
nutrition other than hepatic encephalopathy [13]. Unfortunately, most of the studies analyzed in
that review were too small to provide evidence of satisfactory quality, and so additional studies are
needed to delineate the beneficial effects of this nutritional intervention, including hypoalbuminemia;
increased muscle mass; and cirrhosis-related complications such as infection, gastrointestinal bleeding,
ascites, and hepatic encephalopathy [14].
The present study evaluated the long-term beneficial effects of oral BCAA supplementation by
analyzing various parameters of hepatic function, including the model for end-stage liver disease
(MELD) and Child–Pugh (CP) score, as well as the development of cirrhosis-related events and
hepatocellular carcinoma (HCC).
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2. Materials and Methods
2.1. Study Population
From January 2013 to June 2017, we screened 232 consecutive patients who were clinically or
pathologically diagnosed as having advanced liver cirrhosis with CP scores from 8 to 10 at 14 medical
centers in the Republic of Korea. The main exclusion criteria were viable HCC, advanced Barcelona
Clinic Livre Cancer stage, HCC with a life expectancy of less than 6 months, a recent diagnosis of other
malignancy (within 3 years), finding it impossible to cease alcohol consumption during study period,
serum creatinine level higher than 1.5 mg/dL at the time of enrollment, early liver transplantation
within 6 months after enrollment, and metabolic disorders presenting branched-chain ketoaciduria;
these criteria were also used in a previous retrospective study conducted by our group [15].
2.2. Study Design
The enrolled patients were assigned to two groups: no treatment (control) or treatment with
BCAAs. The BCAA group was treated with 12.45 g of BCAA granules (LIVACT, Samil Pharmaceutical,
Seoul, Korea; 4.15 g of BCAA granules per sachet containing 952 mg of L-isoleucine, 1904 mg of











period,  serum  creatinine  level  higher  than  1.5  mg/dL  at  the  time  of  enrollment,  early  liver 




The enrolled patients were assigned  to  two groups: no  treatment  (control) or  treatment with 













end points  included  the  changes  in  the CP  score and  serum albumin, and  the development  and 
recurrence of HCC, mortality, and cirrhosis‐related complications; these end points were also used 
in the previous retrospective study conducted by our group [15]. 




i re 1. c f t study. * ere c of patients to prescribed BCAAs was > 80%. ,
ra c e -c ain a ino acid.
e re ce f ti ts i t ,
hich was as es ed by each investigator in clinical setting. The control group consumed a standard diet
w thout BCAAs or with only a short course of BCAA treatm n lasting less than 1 month. Patients who
had previously c n umed BCAAs for more than 1 month were excluded at the baseline screening from
both groups. There was no further diet ry intervention of patients xcept standard dietary counseling
of cir hosis in both groups [14].
e primary end point of this tudy was the change in MELD score ver time. The secondary end
points included the changes in the CP score and serum albumin, nd the development and recurrence
of HCC, mortality, and cirrhosis-related complications; these end poin s w r also used in the previous
retrospective study conduct d by our gro p [15].
rit en informed consent was obtained from all patients in both groups. This study was approved
by the institutional review board of each center, and it was conduc ed in accordance with the principles
of the Declaration of H lsinki.
2.3. Baseline Clinical and Laboratory Assessments
The medical history was initially assessed, including previously diagnosed malignancies,
medications that could affect prothrombin activity (e.g., warfarin), recent regular albumin replacement,
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previous and current alcohol consumption, previous and current antiviral treatment for hepatitis B
virus (HBV) or hepatitis C virus (HCV), and previous cirrhosis-related complications. The initial
laboratory data included liver function tests, serum creatinine, viral markers for HBV and HCV, titers of
HBV DNA and HCV RNA (if the patients had HBsAg or HCV antibodies), prothrombin time, CP score,
and MELD score. CP score was calculated by each investigator using assigned points of serum total
bilirubin, serum albumin, prothrombin time, and grades of ascites and hepatic encephalopathy at
the time of enrollment [16]. MELD score was calculated as 9.57 × log (creatinine, mg/dL) + 3.78 log
(bilirubin, mg/dL) + 11.2 × log (INR) + 6.43 (constant for liver disease etiology). Any values used to
calculate MELD score that were less than one were converted to 1.0 [17]. All of the laboratory data were
assessed at least 3 months after resolution of acute liver-related events, including variceal bleeding,
acute infection, hepatic encephalopathy according to West Haven criteria [18], hepatorenal syndrome,
and other acute medical conditions that could affect the CP or MELD score.
2.4. Follow-up Clinical and Laboratory Assessments
To avoid practice variation of all centers, all surveillance of variceal and HCC, and prophylaxis
of varices and spontaneous bacterial peritonitis, adhered to the following current guidelines [14].
Cirrhosis-related complications were assessed by current guideline as well [14]. The event of
cirrhosis-related complication was defined as any medical conditions related to liver cirrhosis that
needed intervention or admission. Major cirrhosis-related events were defined as rupture of varices,
development or aggravation of ascites, hepatorenal syndrome, hepatic encephalopathy, spontaneous
bacterial peritonitis, development or recurrence of HCC, death from any cause, and any life-threatening
medical conditions related to liver cirrhosis except malignancy. The first event of each complication
was counted for complications to compare the development of each complication in both groups.
Regardless of its kind, only the first event was counted for cirrhosis-related events to analyze cumulative
event-free survival. Follow-up data were obtained after 6 months of BCAA treatment or consuming a
regular diet from the BCAA and control groups, respectively. The clinical data included the reason for
visiting the clinic, consumption of alcohol, development and recurrence of HCC, death from any cause,
and liver-related complications. The laboratory data included liver function tests, serum creatinine,
prothrombin time, CP score, and MELD score, which were assessed at the time of visiting the clinic.
2.5. Statistical Analysis
Data were analyzed using IBM SPSS software (version 23.0, IBM, Armonk, NY, USA).
Baseline characteristics were compared between the two study groups using the chi-square test,
Student’s t test, Wilcoxon rank sum test, or a linear-by-linear association test. The changes in the MELD
score, CP score, serum bilirubin, and albumin between the two groups were analyzed using a mixed
linear model. We compared the incidence of liver-related complications, development and recurrence
of HCC, and death using the chi-square test or Fisher’s exact test. The cumulative event-free survival
(EFS) rates were analyzed using the Kaplan–Meier method, and compared using the log-rank test.
We counted the number of patients lost to follow-up or with cirrhosis-related complications or death
from any cause in the analysis. The development and recurrence of HCC were analyzed using Fisher’s
exact test, while factors associated with HCC could not be analyzed due to the low incidence of HCC.
A probability value of p < 0.05 was considered statistically significant.
3. Results
This study screened 232 patients for eligibility, which resulted in the exclusion of 5 patients
with viable HCC, other untreated malignancy, or serum creatinine above 1.5 mg/dL. During the
6-month window period for data inclusion, 104 patients dropped out for the following reasons:
follow-up loss (n = 61), inadequate consumption of BCAAs (n = 19), lack of follow-up data (n = 14),
alcohol consumption (men > 30g/day; women > 20g/day, n = 6), resolution of acute liver-related events
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(n = 3), and early liver transplantation (n = 1). Finally, 124 patients (63 in the BCAA group and 61 in


















Characteristic BCAA Control p values 
Number of patients 63 61 - 
Sex, male 45 (71) 37 (61) 0.281 
Age, years  60 ± 10 58 ± 11 0.742 
BMI, kg/m2  23.0 [21.3-25.1] 22.2 [20.2-24.2] 0.136 
Etiology 
HBV/HCV/alcohol/other 
17/6/31/9 (27/10/49/14) 15/3/38/5 (25/5/62/8) 0.400 
Figure . Flow diagram of the study. HCC, hepatocellular carcinoma; BCAA, branched-chain
amino acid.
3.1. Baseline Characteristics of the Patients
The baseline characteristics did not differ significantly between the two groups (Table 1).
The median follow-up duration also did not differ between the two groups, being 15.2 months
(range = 8.0–19.3 months) in the control group and 16.6 months (range = 11.0–22.2 months) in the BCAA
group (p = 0.111). The median duration of BCAA consumption in the BCAA group was 20.1 months
(range = 11.0–24.0 months). Among the patients with CHB, antiviral agents, including tenofovir and
entecavir, were started due to a high viral load (above 2000 IU/mL) at the time of study enrollment in
seven patients in the BCAA group and five patients in the control group. The serum HBV DNA levels
of the others were below 116 copies/mL regardless of antiviral treatment. Among the patients with
hepatitis C antibodies, HCV RNA was detected in only two patients in the BCAA group, and they were
not treated with interferon plus ribavirin, or direct-acting agents due to the presence of decompensated
cirrhosis or drug nonavailability.
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Table 1. Baseline characteristics in the branched-chain amino acid (BCAA) and control groups.
Characteristic BCAA Control p Values
Number of patients 63 61 -
Sex, male 45 (71) 37 (61) 0.281
Age, years 60 ± 10 58 ± 11 0.742
BMI, kg/m2 23.0 [21.3-25.1] 22.2 [20.2-24.2] 0.136
Etiology
HBV/HCV/alcohol/other 17/6/31/9 (27/10/49/14) 15/3/38/5 (25/5/62/8) 0.400
Child–Pugh score
8/9/10 27/15/21 (43/24/33) 23/16/22 (38/26/36) 0.842
MELD score 14.5 [12.1-16.8] 14.2 [11.9-16.1] 0.914
AST, IU/L 62.0 [36.0-106.0] 59.0 [37.0-134.0] 0.772
ALT, IU/L 31.0 [20.0-41.0] 31.0 [18.0-57-5] 0.447
γ-glutamyl transferase, IU/L 73.0 [32.0-175.0] 106 [25.0-315.0] 0.604
Serum albumin, g/dL 2.7 [2.5-3.1] 2.8 [2.5-3.1] 0.692
Total bilirubin, mg/dL 2.5 [1.9-4.1] 2.7 [2.0-3.8] 0.974
Blood urea nitrogen, mg/dL 11.8 [9.0-16.9] 11.9 [9.2-17.0] 0.675
Serum creatinine (mg/dL) 0.8±0.2 0.8±0.2 0.711
INR 1.4 [1.3-1.5] 1.4 [1.2-1.5] 0.649
Platelet count, ×109/L 100.0 [64.0-134.5] 81.0 [57.0-103.0] 0.079
History of variceal bleeding 47 (74.6) 39 (63.9) 0.274
Hepatic encephalopathy






none/mild/moderate to severe 11/38/14 (18/60/22) 8/39/14 (13/64/23) 0.797
History of HCC 11 (18) 8 (13) 0.673
Data are mean ± SD, median [range] or n (%) values. BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis
C virus; MELD, model for end-stage liver disease; AST, aspartate aminotransferase; ALT, alanine aminotransferase
INR, international normalized ratio; HCC, hepatocellular carcinoma.
3.2. Outcomes Related to Liver Function
The changes in the MELD score, CP score, serum albumin, and bilirubin over 2 years are compared
between the two groups in Figure 3. The MELD and CP scores improved significantly in the BCAA
group over time compared to the control group (p = 0.009 and p = 0.011, respectively). However,
the improvements in serum albumin and bilirubin did not differ significantly over time between the
two groups (p = 0.149 and p = 0.233, respectively). In the subgroup analysis, an improvement in serum
albumin was not demonstrated in patients with serum albumin at 3.5 mg/dL or less, with improvement
only observed in those consuming BCAAs (p = 0.046).
3.3. Cirrhosis-Related Events and HCC
The incidence rates of major cirrhosis-related events and HCC are presented in Table 2.
Major cirrhosis-related events occurred less in the BCAA group than in the control group (p < 0.001),
among which the development or aggravation of ascites and hepatic encephalopathy occurred less
in the BCAA group (p = 0.017 and p = 0.046, respectively). However, the mortality rate did not
differ significantly between the two groups. The cumulative EFS was significantly better in the
BCAA group than in the control group: 605 ± 26 days (95% CI = 555–655 days) vs. 486 ± 28 days
(95% CI = 432–540 days) (p < 0.001, Figure 4). The development and recurrence of HCC did not differ
between the two groups (p = 0.678 and p = 1.000, respectively).
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Event BCAA Control p values 
Number of patients 63 61 - 
Total events except HCC 14 (29) 37 (61) 0.001 
Rupture of varices 2 (3) 6 (10) 0.253 
Development or aggravation of ascites 6 (10) 17 (28) 0.017 
Hepatorenal syndrome 1 (2) 1 (2) 1.000 
Hepatic encephalopathy 6 (10) 15 (25) 0.046 
Spontaneous bacterial peritonitis 2 (3) 1 (2)     1.000 
Other* 0 (0) 1 (2) 0.987 
Figure 3. Changes in the model for end-stage liver disease score (A), Child–Pugh score (B),
serum albumin (C), and total bilirubin (D) in the BCAA and control groups over 2 years.
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Figure 4. Cumulative cirrhosis-related event-free survival in the BCAA and control groups.
BCAA, branched-chain amino acid; CP, Child–Pugh.
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Table 2. Major cirrhosis-related events in the BCAA and control groups.
Event BCAA Control p Values
Number of patients 63 61 -
Total events except HCC 14 (29) 37 (61) 0.001
Rupture of varices 2 (3) 6 (10) 0.253
Development or aggravation of ascites 6 (10) 17 (28) 0.017
Hepatorenal syndrome 1 (2) 1 (2) 1.000
Hepatic encephalopathy 6 (10) 15 (25) 0.046
Spontaneous bacterial peritonitis 2 (3) 1 (2) 1.000
Other * 0 (0) 1 (2) 0.987
Development of HCC 14 (22) 10 (16) 0.553
Recurrence of HCC 7 (11) 4 (7) 0.565
Death 6 (10) 9 (15) 0.537
Data are n (%) values. BCAA, branched-chain amino acid; HCC, hepatocellular carcinoma.
* Other = retroperitoneal hemorrhage.
4. Discussion
This study evaluated the beneficial effects of BCAAs in cirrhotic patients with CP scores from 8 to
10 who were in the decompensated stage rather than the terminal stage. The patients supplemented
with BCAAs for more than 6 months exhibited improved MELD and CP scores compared to those did
not consume BCAAs. Even if treating the underlying liver disease is the most important intervention,
nutritional support is also known to be an independent factor for improving the outcomes in these
patients [4]. Since the underlying liver disease could induce disease progression, all of the patients in
the present study were treated appropriately according to the etiology of their liver disease. All of the
included patients abstained from alcohol consumption and were treated with antiviral agents according
to guidelines when they had chronic viral hepatitis. Thus, most of the clinical parameters, including
MELD score, CP score, serum albumin, and serum bilirubin, were improved in both groups (Figure 2).
However, additional beneficial effects on the MELD and CP scores were demonstrated in the patients
supplemented with BCAAs. An Italian randomized prospective study also found improvements in
CP scores after supplementation with BCAAs in advanced liver disease [2]. However, there have
been no reports based on prospective studies of improvements in MELD scores after supplementation
with BCAAs.
Major cirrhosis-related events occurred less frequently in the BCAA group than in the control
group. Our previous retrospective study failed to show improvement of EFS [15]. The most common
etiology in that previous study was chronic hepatitis B, while it was alcoholic liver disease in the
present study. Unlike other etiologies of liver cirrhosis, ethanol and its metabolites exert direct effects
on the worsening of sarcopenia. Both of these compounds reduce protein synthesis and increase
autophagy via the activation of critical regulatory downstream pathways involving myostatin or
dephosphorylation of mTORC1 and DRP1 [19]. It is therefore possible that these differences in the
etiologies of the analyzed patients are due to the conflicting data.
Among major cirrhosis-related events, the development or aggravation of ascites and
hepatic encephalopathy occurred less frequently in the BCAA group than in the control group.
Moreover, the serum albumin level did not improve in the BCAA group throughout the study period.
However, among the patients with a low albumin level (≤3.5 mg/dL), the serum albumin level improved
in the BCAA group compared to the control group. A Japanese prospective study found improvement
of serum albumin in cirrhotic patients with serum albumin at 3.5 g/dL or less and the presence of
ascites, peripheral edema, or hepatic encephalopathy [20]. The findings of our subgroup analysis are
also supported by a recent study demonstrating that BCAA supplementation improved the survival
rate in cirrhotic patients with sarcopenia and a low albumin level (≤3.5 mg/dL) [21]. It is therefore
possible that this subgroup contributed to the improvement of ascites control in the BCAA group.
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While no improvement in hepatic encephalopathy was found in our previous retrospective
study, the present study found that hepatic encephalopathy developed less frequently in the BCAA
group [15]. It is possible that the early withdrawal of BCAA supplementation in the previous study
is responsible for these conflicting data. Although the beneficial effect of BCAAs has been shown in
several studies, the efficacy of oral BCAAs seems to be modest, and BCAAs are relatively expensive [22].
Thus, oral BCAAs would be considered as an alternative option in patients with hepatic encephalopathy.
The development and recurrence rate of HCC was also analyzed in the present study, but the
relatively small number of patients could have been responsible for no conclusive evidence for
the anticarcinogenic effect of BCAAs being found. An in vitro study produced evidence that the
anticarcinogenic effects of BCAAs are related to down-regulation of insulin-like growth factor-1 receptor
and vascular endothelial growth factor [23,24]. However, its efficacy in clinical studies has only been
shown in relatively small numbers of participants or limited subgroups, such as obese men with high
alpha-fetoprotein [25,26].
The present study was subject to some limitations. First, this study did not have a randomized
controlled design, and so although it was conducted prospectively, selection bias could have influenced
the results. Second, the indication and duration of BCAA supplementation varied between the included
centers, and the dietary habits of the subjects were not tracked. However, BCAA supplementation is
required for at least 6 months, and approximately 70% of the patients in the BCAA group completed
the course of BCAA supplementation during the follow-up period. Third, we could not evaluate the
nutritional status (including sarcopenia) based on anthropometric parameters such as the midarm
muscle circumference, or functional performance such as gait speed or handgrip strength in this study.
However, in the subgroup analysis the level of serum albumin—indicating the nutritional and hepatic
functional status—increased in patients with a low albumin level during BCAA supplementation.
To maintain a better serum albumin level, long-term supplementation with oral BCAAs should be
considered. In addition, future studies should evaluate the beneficial effects of BCAAs in cirrhotic
patients with sarcopenia.
In conclusion, this study has demonstrated that long-term supplementation with oral BCAAs
improved hepatic reservoir parameters, including the MELD and CP scores in patients with advanced
liver disease. The patients supplemented with oral BCAAs exhibited fewer cirrhosis-related
complications, especially the development or aggravation of ascites and hepatic encephalopathy.
Thus, long-term supplementation with oral BCAAs could improve the clinical outcomes of patients
with advanced liver disease.
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